Double hormone blockade may tackle Hard-to-Treat breast cancer

NCT ID NCT05618613

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This trial tests a combination of two drugs, elacestrant and onapristone, in people with a specific type of advanced or metastatic breast cancer that is fueled by the hormones estrogen and progesterone. The goal is to see if blocking both hormone signals at once is safe and can shrink tumors. The study is in early phases and involves a small number of participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of two hormone-blocking drugs: elacestrant and onapristone
What this could lead to
If successful, this combination could offer a new treatment option for people with a specific type of advanced breast cancer that has stopped responding to standard hormone therapies.
What could go wrong
This is an early-phase trial with a small number of participants, so the benefits and risks are not yet well understood. The combination may cause significant side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cancer Treatment Centers of America - Midwestern Regional Center

    Zion, Illinois, 60099, United States

  • Cancer Treatment Centers of America - Western Regional Medical Center

    Phoenix, Arizona, 85338, United States

  • Sarah Cannon Research Institute

    Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.